SCHEMBL5907951

SCHEMBL5907951

O=C1NS(=O)(=O)c2c[c]ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 16/20 0.55
CA9 Q16790 16/20 0.55
CA2 P00918 14/20 0.55
CA7 P43166 7/20 0.55
CA1 P00915 5/20 0.55
KDM4E B2RXH2 1/20 0.55
USP2 O75604 1/20 0.55
LMNA P02545 1/20 0.55
BCHE P06276 1/20 0.55
CA4 P22748 1/20 0.55
CA6 P23280 1/20 0.55
CA5A P35218 1/20 0.55
KMT2A Q03164 1/20 0.55
CA14 Q9ULX7 1/20 0.55
CA5B Q9Y2D0 1/20 0.55
RET P07949 2/20 0.44
GRK5 P34947 2/20 0.44
TYRO3 Q06418 2/20 0.44
DYRK1B Q9Y463 2/20 0.44
CHEK1 O14757 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8810914 0.85 CA12 (0.55) CA12CA9CA2CA7CA1
SCHEMBL9471676 0.75 KDM4E (0.46) CA12CA9CA2CA7CA1
Saccharin SCHEMBL1286764 0.74 CA12 (0.96) CA12CA9CA2CA7CA1
Saccharin SCHEMBL8728937 0.74 CA12 (0.96) CA12CA9CA2CA7CA1
Saccharin SCHEMBL485939 0.72 CA12 (0.92) CA12CA9CA2CA7CA1
Saccharin SCHEMBL1138067 0.72 CA12 (0.92) CA12CA9CA2CA7CA1
Saccharin SCHEMBL1018905 0.72 CA12 (0.92) CA12CA9CA2CA7CA1
Saccharin SCHEMBL6049140 0.71 CA12 (1.00) CA12CA9CA2CA7CA1
Saccharin SCHEMBL4777123 0.71 CA12 (1.00) CA12CA9CA2CA7CA1
Saccharin SCHEMBL7073018 0.71 CA12 (1.00) CA12CA9CA2CA7CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058315-A1 2-Oxo-ethanesulfonamide derivates ASTRAZENECA AB (SE) 2006-03-16 US disclosed
EP-1562574-A1 2-OXO-ETHANESULFONAMIDE DERIVATES Astrazeneca AB (SE) 2005-08-17 EP disclosed
WO-2004041264-A1 2-OXO-ETHANESULFONAMIDE DERIVATES ASTRAZENECA AB (SE) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058315-A1 2-Oxo-ethanesulfonamide derivates HSD11B1, HSD3B1, HSD11B2 CA12 2102/4885CA9 2141/4885CA2 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.